InvestSMART

Patrys Limited (ASX:PAB)

ALERT: Price-sensitive ASX Announcement for PAB
Current share price for PAB : $0.035 -0.002 (-5.41%)+
Announcement
Release
27 Jul 2026 8:28AM
Price at Release
$0.037
Full Release
download
Summary
Patrys Limited presented at the TechKnow Invest Roadshow, outlining their strategy to reformulate the widely used drug quetiapine into an injectable form for faster, lower-risk deployment in ICU settings. This reformulation provides an accelerated development pathway, leveraging the FDA's 505(b)(2) regulatory pathway, which allows the use of existing safety data to speed up the approval process. The new formulation is aimed at addressing a significant unmet need in the treatment of delirium, a condition affecting up to 80% of ICU patients. By utilizing existing clinical data, Patrys aims to reduce development time from the typical 10-15 years and $1.2 billion cost of new drugs to a 3-5 year timeline and $20-30 million in costs. The company has secured intellectual property protection for their injectable formulation, which extends to 2042. The presentation also highlighted the management team's extensive expertise in ASX governance, biotechnology commercialization, and clinical trial operations.
Key Points
  • Patrys is reformulating quetiapine for ICU use.
  • Utilizes FDA 505(b)(2) pathway for accelerated approval.
  • Targeting a $2 billion market for delirium treatment.
  • Development cost of $20-30 million versus $1.2 billion for new drugs.
  • Reformulation reduces development time to 3-5 years.
  • Extensive IP protection until 2042.
  • Management team has significant ASX and biotech expertise.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.